GlassScriptPhysician profile
Phillip Reginald Triplett
NPI 1083645758
$16,574.30
in general payments reported to CMS, 2019-2025
59 companies · $2,413 in 2025
The $2,413 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,614 · 2020: $1,801 · 2021: $1,903 · 2022: $2,144 · 2023: $3,176 · 2024: $2,523 · 2025: $2,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,075 · Education: $36.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,075.35 |
| Education | $36.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,684.88 | 2019-2025 | Enbrel, Otezla, Evenity |
| Abbvie INC. | $2,508.67 | 2019-2025 | Rinvoq, Ubrelvy, Skyrizi |
| Astrazeneca Pharmaceuticals LP | $1,345.67 | 2019-2025 | Saphnelo, Farxiga, Airsupra |
| Lilly USA, LLC | $875.86 | 2019-2025 | Jardiance, Mounjaro, Taltz |
| Janssen Biotech, INC. | $807.17 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $756.89 | 2019-2025 | |
| Glaxosmithkline, LLC. | $755.96 | 2019-2025 | Benlysta, Shingrix, Nucala |
| Novo Nordisk INC | $652.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Ucb, INC. | $601.90 | 2019-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $535.65 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $512.81 | 2019-2025 | Jardiance, Synjardy, Cyltezo |
| Pfizer INC. | $465.06 | 2019-2025 | |
| Amarin Pharma, INC. | $437.87 | 2019-2023 | |
| Aurinia Pharma U.S., INC. | $327.08 | 2021-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $296.60 | 2022-2025 | Purified Cortrophin Gel |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Triplett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.